KaplanJ.G., DesouzaT.G., FarkashA.: Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumor, lymphomas and leukemia. J Neurooncol, 9: 225–229, 1990.
10.
TwijnstraA., Ongerboer de VisserB.W.: Diagnosis of leptomeningeal metastases. Clin Neurol Neurosurg, 89: 79–85, 1987.
11.
PavlidisN.: The diagnostic and therapeutic management of leptomeningeal carcinomatosis. Ann Oncol, 15(Suppl 4): 285–291, 2004.
12.
OrlandoL., CuriglianoG., ColleoniM.: Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. Anticancer Res, 22: 3057–3059, 2002.
13.
IacopettaG., LamaidaE., RossiA.: Leptomeningeal carcinomatosis: review of the literature. Acta Neurol (Napoli), 16: 214–220, 1994.
14.
BleyerW.A.: Leptomeningeal cancer in leukemia and solid tumors. Curr Probi Cancer, 12: 184–238, 1988.
15.
GlantzM.J., HallW.H., ColeB.F.: Diagnosis, management and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer, 75: 2919–2931, 1995.
16.
KohnF.R., MalksumS.A., BrownsonE.A.: Fate of the predominant phospholipid component of DepoFoam drug delivery matrix after intrathecal administration of sustained-release capsulated cytarabine in rats. Drug Delivery, 5: 143–151, 1998.
17.
KimS., ChatelutE., KimJ.C.: Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol, 11: 2186–2193, 1993.
18.
ChamberlainM.C., KhatibiS., KimJ.C.: Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). Arch Neurol, 50: 261–265, 1993.
19.
JaeckleK.A., PhuphanichM.J., Vanden BentM.J.: Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer, 84: 157–163, 2001.
20.
JaeckleK.A., BatchelorT., O'DayS.: A open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol, 57: 231–239, 2002.
21.
GlantzM.J., LaFolleteS., JaeckleK.A.: Randomized trial of slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol, 17: 3110–3116, 1999.
22.
HowellS.B.: Liposomal cytarabine for the treatment of lymphomatous meningitis. Biological therapy of lymphoma, 6: 10–14, 2003.
23.
GlantzM.J., JaeckleK.A., ChamberlainM.C.: A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res, 5: 3394–402, 1995.
24.
ColeB.F., GlantzM.J., JaeckleK.A.: Quality of life adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate of solid tumor. Cancer, 97: 3053–3060, 2003.
25.
SungC., BlaneyS., ColeD.: A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res, 54: 5118–5122, 1994.
26.
BakerS., HeidemanR., CromW.: Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol, 37: 195–202, 1996.
27.
BlaneyS., ColeD., GodwinD.: Intrathecal administration of topotecan in nonhuman primate. Cancer Chemother Pharmacol, 36: 121–124, 1995.
28.
BlaneyS., HeidemanR., BergS.: Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol, 21: 143–147, 2003.
29.
WasserstromW.R., GlassJ.P.: Diagnosis and treatment of leptomeningeal metastases from solid tumor: experience with 90 patients. Cancer, 49: 759–772, 1982.
30.
ChenY.M., ChenM.C., TsaiC.M., PerngR.P.: Intrathecal gemcitabine chemotherapy for non small cell lung patients with meningeal carcinomatosis. A case report. Lung Cancer, 40: 99–101, 2003.
31.
LaufmanL.R., ForsthoefelK.F.: Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer, 2: 235, 2001.
32.
YaysonG.C., HowellA.: Carcinomatous meningitis in solid tumors. Ann Oncol, 7: 773–775, 1996.
